Coverage change brief — sample issue

This is a real issue, built from live sources in October 2026, with the customer's name removed. A subscriber's issue is scoped to their own codes, payers and states, so the items below would differ. Everything else — structure, sourcing, level of detail — is exactly what arrives on Thursday.

The three things that matter this month

1. Medicare's ambulatory cardiac monitoring framework is now live, and it is class-aware. Noridian finalized LCD L40255 (Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices) — effective 21 June 2026, current revision 13 August 2026 — and it distinguishes device classes (mobile cardiac telemetry vs. patch vs. implantable loop) instead of applying MCT requirements to everything. Palmetto and CGS ran the same comment period and are expected to follow. This is the single most consequential document for the category this year.
2. Commercial prior authorization is moving in both directions at once. UnitedHealthcare dropped roughly 1,700 codes from prior authorization on 1 October 2026 and cuts PA for members under 18 on 1 December 2026 — while its CGM prior-auth bypass in Maine ends 1 January 2027. Category-level PA relief does not mean category-level payment certainty.
3. Medicare is starting to pay for outcomes instead of device usage. The ACCESS model went live 6 July 2026 with more than 160 participating organizations, and pays on measured improvement rather than activity. Its 2027 expansion to heart failure and COPD is the first structural change to the economics of standalone remote monitoring.

Items

1. Noridian final LCD L40255 — ambulatory cardiac monitoring

Changed: Final LCD published 7 May 2026, effective 21 June 2026, revision current as of 13 August 2026. Coverage expanded to reflect newer technologies and to preserve access to arrhythmia detection.
Applies to: contractors 02101 (AK), 02201 (ID), 02301 (OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), 03601 (WY).
Why it matters to you: the criteria are written per device class. If your submission or billing team is still using the pre-2026 interpretation — all ambulatory cardiac monitoring treated as MCT — you are arguing against a policy that no longer exists, or claiming coverage you cannot support.
Action this week: confirm which device class the product is billed under, and re-read the transmission and monitoring requirements against your actual workflow.

Source: Noridian article — final LCD effective 21 June 2026

2. The notice mechanics behind L40255

Changed: Proposed LCD DL40255 sat in notice from 7 May 2026 to 20 June 2026 before becoming L40255.
Why it matters: a coverage decision that can move a whole category gives you roughly six weeks of warning — enough to comment, adjust messaging, or prepare an appeal template, but only if someone is watching the proposed-LCD feed.

Source: CMS Medicare Coverage Database — proposed LCD report

3. UnitedHealthcare — October 2026 policy and protocol update

Changed: roughly 1,700 procedure and treatment codes removed from prior authorization effective 1 October 2026, concentrated in selected diagnostic services, procedures, therapy services and DME. Additional changes: prior-auth reductions for members under 18 from 1 December 2026; new Part B step-therapy PA requirements and oncology HCPCS PA from 1 January 2027; new AMA genetic and molecular codes added quarterly.
Why it matters: "PA removed" is a billing opportunity and a documentation trap — no PA does not mean no post-payment review.
Action: pull the published code list against your CPTs and flag any overlap before the next claim cycle.

Source: UnitedHealthcare — October monthly overview

4. UnitedHealthcare — Maine CGM prior-auth bypass ends

Changed: the MCT2D CGM prior-auth bypass pilot ends 1 January 2027.
Why it matters: state-level pilots expire quietly and revert to standard PA. Any volume in that channel needs a plan for January.

Source: same UnitedHealthcare October overview.

5. Aetna CPB 0011 — a category flipped from denied to covered in one bulletin

Changed: on 15 October 2026, Aetna's Clinical Policy Bulletin 0011 moved percutaneous electrical nerve field stimulation (IB-Stim) from experimental/investigational to medically necessary DME for functional abdominal pain, effective immediately, across roughly 26 million members.
Why it matters: this is the template for how a category can move. No CPT change, no fee-schedule change — one bulletin, one day, a market opened. It is also the argument for watching bulletins rather than fee schedules.

Source: Aetna Clinical Policy Bulletin index

6. Cigna — site-of-care restrictions expanding

Changed: 8 October 2026 — the Specialty Medical Injectables reimbursement-restriction list was expanded (restriction applies when administered in an outpatient hospital setting): Zanvastro effective 28 September 2026; Blincyto, Datroway, Imdelltra, Jelmyto, Keytruda, Lynozyfic, Rylplazim, Talvey, Texcayli, Unloxcyt and Zusduri effective 1 January 2027. Separately, on 16 October 2026, four drugs were added to the Pathwell Specialty list effective 1 October 2026.
Why it matters: site-of-service is where device-adjacent procedure coverage is being squeezed. If monitoring is delivered alongside infusion or in-hospital workflows, this is the direction of travel.

Source: Cigna provider newsroom — injectables restriction

7. CMS ACCESS — outcome-aligned payment for technology-supported care

Changed: ACCESS went live 6 July 2026; more than 160 organizations are participating. It is a 10-year model paying for measured outcomes across four tracks (early cardio-kidney-metabolic, cardio-kidney-metabolic, musculoskeletal, behavioral health), with annual allowed amounts in the low hundreds of dollars per patient and a co-management payment of roughly $30 for referring clinicians. A vendor directory for connected devices is planned. Expansion to heart failure and COPD is slated for 2027.
Why it matters: if a meaningful share of revenue depends on per-usage RPM billing, this is the first credible replacement logic — and a reason to be in the ACCESS vendor conversation early rather than after the directory is full.

Source: CMS — ACCESS for primary care and referring clinicians · technical FAQ

Next 90 days — dates to hold

• 1 December 2026 — UnitedHealthcare prior-auth reductions for members under 18 take effect.
• 1 January 2027 — UHC Maine CGM PA bypass ends; Part B step-therapy and oncology HCPCS PA begin; Cigna's additional injectables join the outpatient-hospital restriction list.
• 2027, date to be determined — ACCESS expands to heart failure and COPD; ACCESS vendor directory opens.
• Ongoing — Palmetto and CGS are expected to post their versions of the ambulatory cardiac monitoring LCD; none has been confirmed as final.

Sources checked for this issue

CMS Medicare Coverage Database (final and proposed LCDs, policy articles), the four DME MACs, six national commercial payer policy libraries (Aetna CPB, Cigna coverage policies and provider newsroom, UnitedHealthcare medical and reimbursement policy, Anthem/Elevance and Humana), the Federal Register, and state Medicaid provider bulletins for the ten states in scope.

Scope and disclaimer

Everything in this issue is a factual change with a link to the primary source. There is no clinical or legal advice in this document and no coverage determination; those remain with the payer and the treating clinician. If a source could not be reached, this section would name it.